Iradimed Corp Reports Record Q1 2025 Revenue

Iradimed Corp ( (IRMD) ) has released its Q1 earnings. Here is a breakdown of the information Iradimed Corp presented to its investors.

Iradimed Corporation, a leader in developing MRI-compatible medical devices, specializes in non-magnetic intravenous infusion pump systems and patient vital signs monitoring systems designed for use during MRI procedures.

The company reported record revenue of $19.5 million for the first quarter of 2025, marking an 11% increase compared to the same period in 2024. Additionally, Iradimed announced a regular quarterly cash dividend of $0.17 per share and reaffirmed its full-year 2025 revenue and earnings guidance.

Key financial highlights include a GAAP diluted EPS of $0.37 and a non-GAAP diluted EPS of $0.42, reflecting increases of 16% and 17% respectively from the previous year. The company’s net income rose to $4.7 million, a 15% increase, while cash flow from operations also improved by 10% year-over-year. Iradimed’s domestic sales accounted for 82% of total revenue, and the gross profit margin remained steady at 76.1%.

Looking ahead, Iradimed expects second-quarter 2025 revenue to range between $19.7 million and $19.9 million, with full-year revenue projected between $78.0 million and $82.0 million. The company is on track to complete its new manufacturing facility by July 2025, positioning it for continued growth and operational excellence.